NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses. NovaBay Pharmaceuticals, Inc. has collaboration and license agreement with Virbac to develop auriclosene, a proprietary compound for veterinary markets. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:NBY
CUSIPN/A
Phone+1-510-8998800
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-59.81%
Return on Equity-389.40%
Return on Assets-84.88%
Miscellaneous
EmployeesN/A
Outstanding Shares17,090,000
NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Frequently Asked Questions
What is NovaBay Pharmaceuticals' stock symbol?
NovaBay Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NBY."
When did NovaBay Pharmaceuticals' stock split? How did NovaBay Pharmaceuticals' stock split work?
NovaBay Pharmaceuticals's stock reverse split on the morning of Monday, December 21st 2015. The 1-25 reverse split was announced on Friday, December 11th 2015. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 18th 2015. An investor that had 100 shares of NovaBay Pharmaceuticals stock prior to the reverse split would have 4 shares after the split.
How were NovaBay Pharmaceuticals' earnings last quarter?
NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) posted its quarterly earnings data on Tuesday, November, 14th. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the Zacks' consensus estimate of ($0.07) by $0.09. The biopharmaceutical company had revenue of $4.09 million for the quarter, compared to analysts' expectations of $4.69 million. NovaBay Pharmaceuticals had a negative return on equity of 389.40% and a negative net margin of 59.81%. View NovaBay Pharmaceuticals' Earnings History.
What price target have analysts set for NBY?
4 brokers have issued twelve-month price targets for NovaBay Pharmaceuticals' shares. Their forecasts range from $4.00 to $8.00. On average, they anticipate NovaBay Pharmaceuticals' stock price to reach $5.6667 in the next year. View Analyst Ratings for NovaBay Pharmaceuticals.
Who are some of NovaBay Pharmaceuticals' key competitors?
Some companies that are related to NovaBay Pharmaceuticals include Arix Bioscience (ARIX), Mereo BioPharma Group (MPH), Ampio Pharmaceuticals (AMPE), Immupharma (IMM), Verona Pharma (VRP), Emblem (EMC), Cannabics Pharmaceuticals (CNBX), Oxford Biodynamics (OBD), Verseon (VSN), Silence Therapeutics (SLN), Trillium Therapeutics (TRIL), Tiziana Life Sciences (TILS), Bioventix (BVXP), Medicure Inc. Common Stock (MPH) and Oncolytics Biotech (ONC).
Who are NovaBay Pharmaceuticals' key executives?
NovaBay Pharmaceuticals' management team includes the folowing people:
- Mr. Mark M. Sieczkarek, Chairman, CEO & Pres (Age 63)
- Mr. Justin M. Hall, Sr. VP & Gen. Counsel (Age 40)
- Mr. John J. McGovern, CFO, Treasurer & Principal Accounting Officer
- Dr. David W. Stroman Ph.D., Sr. VP of Ophthalmic Product Devel. and Chair of Ophthalmology Advisory Board (Age 73)
- Mr. Lewis J. Stuart BA, MBA, Chief Commercial Officer (Age 59)
Has NovaBay Pharmaceuticals been receiving favorable news coverage?
Media coverage about NBY stock has been trending somewhat positive on Wednesday, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. NovaBay Pharmaceuticals earned a media sentiment score of 0.12 on Accern's scale. They also assigned media coverage about the biopharmaceutical company an impact score of 45.99 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
How do I buy shares of NovaBay Pharmaceuticals?
Shares of NBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is NovaBay Pharmaceuticals' stock price today?
One share of NBY stock can currently be purchased for approximately $2.55.
How big of a company is NovaBay Pharmaceuticals?
NovaBay Pharmaceuticals has a market capitalization of $52.51 million.
How can I contact NovaBay Pharmaceuticals?
NovaBay Pharmaceuticals' mailing address is 2000 Powell St Ste 1150, EMERYVILLE, CA 94608-1804, United States. The biopharmaceutical company can be reached via phone at +1-510-8998800.
MarketBeat Community Rating for NovaBay Pharmaceuticals (NBY)
MarketBeat's community ratings are surveys of what our community members think about NovaBay Pharmaceuticals and other stocks. Vote "Outperform" if you believe NBY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NBY will underperform the S&P 500 over the long term. You may vote once every thirty days.
